Show simple item record

dc.contributor.authorJong JC de
dc.contributor.authorBestebroer TM
dc.contributor.authorBijlsma K
dc.contributor.authorVerweij C
dc.date.accessioned2012-12-12T14:13:34Z
dc.date.available2012-12-12T14:13:34Z
dc.date.issued1994-02-28
dc.identifier118114001
dc.identifier.urihttp://hdl.handle.net/10029/256570
dc.description.abstractAbstract niet beschikbaar
dc.description.abstractInfluenza virus is subject to frequent antigenic changes. As a consequence, the World Health Organization (WHO) operates a world-wide laboratory network to monitor these changes. RIVM participates in this system. It isolates influenza virus strains from clinical specimens obtained from a sentinel station network of general practitioners. It also compares Dutch virus strains with foreign virus strains and with the virus strains used in the current influenza vaccine. The results are reported to the WHO and to the Ministry of Health of the Netherlands. The results of such comparisons enable the Dutch health authorities to consider adaptations of the WHO-proposal about the vaccine for the next season to the epidemiological situation in the Netherlands. A total of 256 influenza A virus strains isolated in 1990-1992 in the Netherlands and other countries were analysed by haemagglutination-inhibition (HI) tests using ferret antisera and monoclonal antibodies and, partly, by determination of the nucleotide sequences of the haemagglutinin gene (HA1). In the season 1991/92, most strains belonged to the subtype A(H3N2), a minority to the subtype A(H1-N1). The overall antigenic structure was similar to that of the corresponding vaccine strain for both subtypes. This means that the influenza vaccine will have rendered optimal protection against the circulating virus strains in 1991/92. A markedly heterogeneous geographic distribution was noted with the two most frequently isolated HI-variants of subtype A(H3N2). One prevailed in the Netherlands and in Spain, the other in Sweden, France, and the United States. Even within the Netherlands the proportions of the two variants showed regional variation. This heterogeneity did not have implications for the vaccine efficacy.
dc.description.sponsorshipGHI
dc.format.extent59 p
dc.language.isoen
dc.relation.ispartofRIVM Rapport 118114001
dc.relation.urlhttp://www.rivm.nl/bibliotheek/rapporten/118114001.html
dc.subject01nl
dc.subjectinfluenza virussennl
dc.subjectsurveillancenl
dc.subjectantigenennl
dc.subjectorthomyxoviridaeen
dc.subjectsurveillanceen
dc.subjectantigensen
dc.subjectantigenic changesen
dc.subjectnucleotide sequence analysisen
dc.titleAntigenic and molecular surveillance of influenza virus strains in the period 1990-1992en
dc.title.alternative[Antigene en moleculaire surveillance van influenzavirusstammen in de periode 1990-1992.]nl
dc.typeReport
dc.contributor.departmentVIR
dc.date.updated2012-12-12T14:13:35Z
html.description.abstractAbstract niet beschikbaar
html.description.abstractInfluenza virus is subject to frequent antigenic changes. As a consequence, the World Health Organization (WHO) operates a world-wide laboratory network to monitor these changes. RIVM participates in this system. It isolates influenza virus strains from clinical specimens obtained from a sentinel station network of general practitioners. It also compares Dutch virus strains with foreign virus strains and with the virus strains used in the current influenza vaccine. The results are reported to the WHO and to the Ministry of Health of the Netherlands. The results of such comparisons enable the Dutch health authorities to consider adaptations of the WHO-proposal about the vaccine for the next season to the epidemiological situation in the Netherlands. A total of 256 influenza A virus strains isolated in 1990-1992 in the Netherlands and other countries were analysed by haemagglutination-inhibition (HI) tests using ferret antisera and monoclonal antibodies and, partly, by determination of the nucleotide sequences of the haemagglutinin gene (HA1). In the season 1991/92, most strains belonged to the subtype A(H3N2), a minority to the subtype A(H1-N1). The overall antigenic structure was similar to that of the corresponding vaccine strain for both subtypes. This means that the influenza vaccine will have rendered optimal protection against the circulating virus strains in 1991/92. A markedly heterogeneous geographic distribution was noted with the two most frequently isolated HI-variants of subtype A(H3N2). One prevailed in the Netherlands and in Spain, the other in Sweden, France, and the United States. Even within the Netherlands the proportions of the two variants showed regional variation. This heterogeneity did not have implications for the vaccine efficacy.


This item appears in the following Collection(s)

Show simple item record